Nabota and Dysport are both prescription-only injectable neurotoxins used primarily to temporarily improve the appearance of moderate to severe frown lines between the eyebrows (glabellar lines). The fundamental difference lies in their origin and specific molecular formulation. Dysport (abobotulinumtoxinA) is a product with a long-standing global presence, developed by the Irish pharmaceutical company Ipsen. In contrast, Nabota (prabotulinumtoxinA-xvfs) is a newer, high-purity botulinum toxin type A product from South Korea’s Daewoong Pharmaceutical, which gained FDA approval more recently. While both are derived from the same bacterium, Clostridium botulinum, the proprietary manufacturing processes result in distinct molecular sizes and protein complex weights, which can influence their diffusion characteristics and unit dosing.
To understand these differences in depth, it’s helpful to look at their core specifications side-by-side.
| Feature | Nabota (prabotulinumtoxinA) | Dysport (abobotulinumtoxinA) |
|---|---|---|
| Manufacturer | Daewoong Pharmaceutical (South Korea) | Ipsen (Ireland) |
| FDA Approval (U.S.) | 2019 for glabellar lines | 2009 for glabellar lines |
| Molecular Complex Size | Approx. 900 kDa (relatively larger core toxin) | Approx. 500-900 kDa (a range of complex sizes) |
| Protein Content | Contains only the 900kDa neurotoxin complex; marketed as high-purity with low protein load. | Contains the neurotoxin and accessory proteins. |
| Reconstitution | Typically supplied as 100-unit vials. | Typically supplied as 300-unit or 500-unit vials. |
| Common Conversion Ratio* | 1:1 (compared to Botox) | Often cited at a 2.5:1 or 3:1 ratio to Botox (e.g., 2.5-3 units of Dysport per 1 unit of Botox/Nabota) |
*Note: Unit conversion is not standardized and is a critical clinical decision made by the injector based on their experience and the patient’s anatomy.
Molecular Profile and How They Work
Both Nabota and Dysport function identically at the neurological level. They block the release of acetylcholine, the chemical messenger that signals your muscles to contract. By inhibiting this signal in targeted facial muscles, they cause a temporary reduction in muscle activity, leading to a smoothing of the overlying skin and a reduction in the appearance of dynamic wrinkles.
The key practical difference stems from their molecular size and diffusion properties. Diffusion refers to how the product spreads from the injection site after it’s administered.
- Dysport is often described as having a broader area of diffusion. This can be advantageous for treating larger areas like the forehead, where a more even spread is desirable. However, it requires a highly skilled injector to ensure the product does not migrate to adjacent muscles, which could cause unwanted side effects like a droopy eyelid (ptosis) when treating the glabella.
- Nabota is characterized by a more localized diffusion pattern. Its larger 900kDa core toxin complex is thought to stay closer to the injection point. This targeted action can be a significant benefit for precision work, such as defining the delicate areas around the eyes (crow’s feet) or specifically targeting the frown lines without affecting the eyebrow lift muscles. This precision potentially offers a lower risk of ptosis. For a deeper dive into its clinical profile, you can explore resources at Nabota.
Clinical Performance: Onset, Duration, and Efficacy
When choosing a treatment, patients and practitioners are keenly interested in how quickly it works, how long it lasts, and how effective it is.
Onset of Action: Dysport has a reputation for a very rapid onset. Many patients report noticing a softening of lines within 24-48 hours, with full effects visible in 2-3 days. Nabota also has a relatively quick onset, with studies showing a median onset of 2-3 days, and full effects typically seen within a week. For some individuals, the speed may be comparable, but Dysport often holds a slight edge in the first few days.
Duration of Effect: This is a crucial factor for long-term satisfaction. Clinical studies for both products demonstrate a duration of approximately 3-4 months for the treatment of glabellar lines. However, duration is highly individual and can be influenced by the patient’s metabolism, muscle mass, the dose administered, and the injection technique. Some users of both products report effects lasting up to 5-6 months with repeated treatments, as the muscles can become trained to relax.
Efficacy: Both Nabota and Dysport have robust clinical trial data proving their high efficacy in reducing the severity of glabellar lines. In pivotal trials, over 90% of patients showed improvement at maximum frown. From a practical standpoint, when administered by an experienced professional at appropriate doses, the final aesthetic outcome—smoother, rejuvenated skin—is often very similar between the two.
Safety Profile and Potential Side Effects
All botulinum toxin type A products have an excellent safety profile when used correctly. The most common side effects are mild and temporary, including injection site reactions like redness, swelling, bruising, or mild pain. Headache can also occur occasionally.
The risk of more significant side effects is low but is directly tied to the injector’s skill and understanding of facial anatomy. As mentioned, due to its diffusion profile, there is a theoretical concern with Dysport regarding a slightly higher risk of diffusion-related events like ptosis if not placed precisely. Nabota’s more localized spread may mitigate this risk. However, a skilled injector using proper technique and dosage can minimize these risks with either product.
It is paramount that patients disclose their full medical history, as these products are contraindicated in individuals with certain neurological disorders, allergies to any ingredient, or active infections at the injection site.
Practical Considerations: Cost and Accessibility
Dysport has been on the market for over a decade and is widely available in clinics across the United States and Europe. Its established presence means most experienced injectors are very familiar with its properties.
Nabota, as a newer entrant, may be offered at a more competitive price point as manufacturers and clinics aim to introduce it to the market. This can make it an attractive option for cost-conscious consumers seeking a high-quality, FDA-approved neurotoxin. However, its availability might be more limited compared to Dysport, depending on your geographic location and the clinic’s preferred suppliers. It’s always best to consult with a board-certified dermatologist or plastic surgeon who can assess your individual needs and recommend the most suitable product based on their expertise and your aesthetic goals.
The choice between Nabota and Dysport isn’t about one being definitively “better” than the other. It’s about finding the right tool for the job. A master injector will consider your facial structure, the specific muscles being targeted, your desired outcome, and their own experience to select the product that will deliver the safest and most natural-looking results for you. An open consultation is the most critical step in this process.